Mankind Pharma Limited
MANKIND · Pharma · NSE
₹2,105
Current Market Price
Fair Value (DCF)
₹1,299
Margin of Safety
-38.3%
Updated 9h ago
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
41%
ROE
13.7%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.87 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.3%
Return on capital employed
EV / EBITDA
26.5×
Enterprise multiple
Debt / EBITDA
2.4×
Leverage vs earnings
Interest Coverage
7.0×
EBIT covers interest
Current Ratio
1.23×
Short-term liquidity
Asset Turnover
0.48×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,104.8
Bear case
₹740.9
MoS -184.1%
Base case
₹1,298.53
MoS -62.1%
Bull case
₹1,830.16
MoS -15.0%
Ratio Trends
MANKIND · last 4 annual periods
ROE
13.7%
ROCE
15.4%
Operating Margin
—
Debt / Equity
0.58×
PE
—
EV / EBITDA
—
Historical Financials
MANKIND · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹7782 Cr | ₹2053 Cr | ₹2441 Cr | ₹12.2K Cr | +16.2% |
| EBITDA | ₹2197 Cr | ₹2037 Cr | ₹2824 Cr | ₹3558 Cr | +17.4% |
| EBIT | — | ₹380 Cr | ₹579 Cr | — | +15.1% |
| PAT | ₹1433 Cr | ₹294 Cr | ₹477 Cr | ₹1991 Cr | +11.6% |
| EPS (diluted) | — | ₹7.13 | ₹11.74 | — | +18.1% |
| CFO | ₹920 Cr | ₹1813 Cr | ₹2152 Cr | ₹2413 Cr | +37.9% |
| CapEx | ₹-2346 Cr | — | — | ₹-531 Cr | — |
| FCF | ₹-1426 Cr | — | — | ₹1883 Cr | — |
| Total Assets | ₹9148 Cr | ₹9715 Cr | ₹12.0K Cr | ₹27.8K Cr | +44.8% |
| Total Debt | ₹873 Cr | ₹142 Cr | ₹175 Cr | ₹8511 Cr | +113.6% |
| Shareholders' Equity | ₹6316 Cr | ₹7435 Cr | ₹9363 Cr | ₹14.6K Cr | +32.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MANKIND vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| ZYDUSLIFE Zydus Lifesciences Limited | +47.7% | 45 | Data Limited | 17.2% | — |
| AUROPHARMA Aurobindo Pharma Limited | +36.3% | 59 | Undervalued | 10.7% | — |
| CIPLA Cipla Limited | +43.1% | 66 | Data Limited | 16.9% | 22.1× |
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| LUPIN Lupin Limited | +16.1% | 37 | Undervalued | 19.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1.00/sh
Last payout
2025-08-08
₹1.00
Peak payout
₹1.00
Trailing yield
0.05%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Mankind Pharma Limited (MANKIND.NS) trades at 2104.80 vs a model fair value of 1298.53, a gap of -38.3%. Piotroski F-score: 5/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MANKIND →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MANKIND →
Compare
Head-to-head with peers
Compare MANKIND side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MANKINDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.